P. F. Halloran, Immunosuppressive drugs for kidney transplantation, N Engl J Med, vol.351, p.2715, 2004.

S. A. Lodhi, K. E. Lamb, and M. Hu, Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success, Am J Transplant, vol.11, p.1226, 2011.

M. D. Stegall, R. S. Gaston, F. G. Cosio, and A. Matas, Through a glass darkly: seeking clarity in preventing late kidney transplant failure, J Am Soc Nephrol, vol.26, p.20, 2015.

K. E. Lamb, S. Lodhi, and H. Meier-kriesche, Long-term renal allograft survival in the United States: a critical reappraisal, Am J Transplant, vol.11, p.450, 2011.

R. B. Colvin, Antibody-mediated renal allograft rejection: diagnosis and pathogenesis, J Am Soc Nephrol, vol.18, p.1046, 2007.

D. Dragun, A. Philippe, and R. Catar, Role of non-HLA antibodies in organ transplan-tation, Curr Opin Organ Transplant, vol.17, p.440, 2012.

K. J. Tinckam and A. Chandraker, Mechanisms and role of HLA and non-HLA alloantibodies, Clin J Am Soc Nephrol, vol.1, p.404, 2006.

D. Dragun, R. Catar, and P. A. , Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance, Curr Opin Organ Transplant, vol.18, p.430, 2013.

A. A. Zachary, R. A. Montgomery, S. C. Jordan, N. L. Reinsmoen, F. Claas et al., 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation, vol.69, p.160, 2007.

G. Riemekasten, P. A. , and M. , Involvement of functional autoan-tibodies against vascular receptors in systemic sclerosis, Ann Rheum Dis, vol.70, p.530, 2011.

D. Dragun, Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation, Transplantation, vol.86, p.1019, 2008.

N. L. Reinsmoen, Role of angiotensin II type 1 receptor-activating antibodies in solid organ transplantation, Hum Immunol, vol.74, p.1474, 2013.

D. Dragun, . Dn, and J. H. Br?-asen, Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection, N Engl J Med, vol.352, p.558, 2005.

Y. Xia and R. E. Kellems, Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond, Circ Res, vol.113, p.78, 2013.
DOI : 10.1161/circresaha.113.300752
URL : https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.113.300752

M. Taniguchi, L. M. Rebellato, and J. Cai, Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies, Am J Transplant, vol.13, p.2577, 2013.

J. Lee, K. H. Huh, and Y. Park, The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation, Nephrol Dial Transplant, p.375, 2015.

H. Lee, J. Kim, and I. Moon, Investigation of serum angiotensin II type 1 receptor antibodies at the time of renal allograft rejection, Ann Lab Med, vol.35, p.314, 2015.

M. H. Pearl, R. K. Leuchter, E. F. Reed, Q. Zhang, R. B. Ettenger et al., Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies, Pediatr Nephrol, vol.30, p.1371, 2015.

A. Jobert, N. Rao, and S. Deayton, Angiotensin II type 1 receptor antibody precipitating acute vascular rejection in kidney transplantation, Nephrology Carlton, vol.20, p.10, 2015.

M. Banasik, M. Boraty-nska, and K. Ko-scielskakasprzak, The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes

, Transpl Int, vol.27, p.1029, 2014.

A. Fuss, C. M. Hope, and S. Deayton, C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies, Nephrology Carlton, vol.20, p.467, 2015.

J. W. In, H. Park, and E. Y. Rho, Antiangiotensin type 1 receptor antibodies associated with antibody-mediated rejec-tion in patients without preformed HLA-donor-specific antibody, Transplant Proc, vol.46, p.3371, 2014.

P. M. Kimball, G. Gupta, and F. Mcdougan, Circulating angiotensin type II receptor: possible marker for antibody mediated rejection after renal transplantation?, Hum Immunol, vol.pii, issue.17, pp.30093-30102, 2017.

J. Zhang, M. Wang, J. Liang, M. Zhang, X. Liu et al., The presence of antiangiotensin II type-1 receptor antibodies adversely affect kidney graft outcomes, Int J Environ Res Public Health, vol.14, p.500, 2017.

M. Giral, Y. Foucher, and A. Dufay, Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss, Am J Transplant, vol.13, p.2567, 2013.

F. Gillaizeau, M. Giral, E. Dantan, D. Dragun, J. Soulillou et al.,

, Multi-state analysis of kidney transplant recipients outcome: a semi-Markov model for studying the role of pretransplant sensitization against Angiotensin II Type 1 receptor, J Soc Fr Statistique, vol.155, p.117, 2014.

K. Solez, R. B. Colvin, and L. C. Racusen, Banff 07 classification of renal allograft pathology: updates and future directions, Am J Transplant, vol.8, p.753, 2008.

B. J. Nankivell, R. J. Borrows, C. Fung, O. Connell, P. J. Allen et al., Natural history, risk factors, and impact of subclinical rejection in kidney transplantation, Transplantation, vol.78, p.242, 2004.

M. Mengel, J. R. Chapman, and F. G. Cosio, Protocol biopsies in renal transplantation: insights into patient management and pathogenesis, Am J Transplant, vol.7, p.512, 2007.

M. Noordzij, K. J. Leffondr-e-k,-van-stralen, C. Zoccali, F. W. Dekker, and K. J. Jager, When do we need competing risks methods for survival analysis in nephrology?, Nephrol Dial Transplant, vol.28, p.2670, 2013.

P. M. Grambsch and T. M. Therneau, Proportional hazards tests and diagnostics based on weighted residuals, Biometrika, vol.81, p.515, 1994.

M. Schemper and T. L. Smith, A note on quantifying follow-up in studies of failure time, Control Clin Trials, vol.17, p.343, 1996.

O. Aalen and S. Johansen, An empirical transition matrix for non-homogeneous Markov chains based on censored observations, 1978.

. R-core-team and . Va, R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing

A. C. Justice, K. E. Covinsky, and J. A. Berlin, Assessing the generalizability of prognostic information, Ann Intern Med, vol.130, p.515, 1999.

P. Royston and D. G. Altman, External validation of a Cox prognostic model: principles and methods, BMC Med Res Methodol, vol.13, p.33, 2013.

D. Cantarovich, G. Karam, and M. Hourmant, Steroid avoidance versus steroid withdrawal after simultaneous pancreaskidney transplantation, Am J Transplant, vol.5, p.1332, 2005.

J. Malheiro, L. S. Martins, and S. Tafulo, Impact of de novo donor-specific anti-HLA antibodies on grafts outcomes in simultaneous pancreas-kidney transplantation, Transpl Int, vol.29, p.173, 2016.

H. Ekberg, H. Tedesco-silva, and A. Demirbas, Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med, vol.357, p.2562, 2007.

E. A. Hern-andez-m-endez, J. M. Arreola-guerra, and L. E. Morales-buenrostro, Pretransplant angiotensin II type 1 receptor antibodies: a risk factor for decreased kidney graft function in the early posttransplant period?, Rev Invest Clin, vol.66, p.218, 2014.

J. Gough, D. Rush, and J. Jeffery, Reproducibility of the Banff schema in reporting protocol biopsies of stable renal allografts, Nephrol Dial Transplant, vol.17, p.1081, 2002.

E. Cuevas, J. Arreola-guerra, E. Hernandezmendez, and I. Salcedo, Are AT1R antibodies as dangerous as HLA-DSAs in renal allografts?

, American Transplant Congress, Am J Transplant, vol.15, p.23, 2015.

J. J. Meerpohl, L. K. Schell, and D. Bassler, Evidence-informed recommendations to reduce dissemination bias in clinical research: conclusions from the OPEN (Overcome failure to Publish nEgative fiNdings) project based on an international consensus meeting, BMJ Open, vol.5, p.6666, 2015.